Epalrestat at the Nexus of Metabolism and Neuroprotection...
2025-10-21
This thought-leadership article unveils how Epalrestat, a potent and high-purity aldose reductase inhibitor, is redefining the frontiers of translational research. We explore the mechanistic underpinnings of polyol pathway inhibition in diabetic complications, neurodegeneration, oxidative stress, and—drawing on the latest cancer metabolism research—the emerging therapeutic potential in oncology. With a focus on the KEAP1/Nrf2 pathway and recent literature linking fructose metabolism to malignancy, we provide actionable strategies and expert guidance for researchers seeking to leverage Epalrestat in high-impact experimental pipelines.